Testing adebrelimab, apatinib, and HAIC for bile duct cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests if adding a combination of immunotherapy (adebrelimab), a targeted drug (apatinib), and chemotherapy into the liver artery (HAIC) before and after surgery can help people with resectable intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to see if this approach improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of intrahepatic cholangiocarcinoma (a type of bile duct cancer) that can be removed with surgery.
- Your cancer is at stage Ib to IIIb (spread within the liver but not to distant organs).
- You are 18 years or older.
- You are in good physical condition (ECOG score 0 or 1, meaning you are fully active or able to do light work).
- Your blood work and organ function meet certain safety levels (like enough white blood cells, normal kidney and liver function).
- You have not had any previous treatment for this tumor (except if you had surgery for bile duct cancer at least 2 years ago and it came back).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of treatments for intrahepatic cholangiocarcinoma (a bile duct cancer in the liver) that cannot be surgically removed. It combines chemo directly into the liver with two drugs that boost the immune system and block blood vessel growth, hoping to shrink the tumor and help you live longer.
This trial tests a combination of drugs to treat advanced bile duct cancer that cannot be removed by surgery. The treatment may help shrink tumors and improve outcomes.
This trial tests a combination of chemotherapy (gemcitabine and cisplatin) with the targeted therapy lenvatinib and the immunotherapy adebrelimab for people with advanced bile duct cancer that cannot be removed by surgery. It aims to see if this combination works better than standard treatments.
This study tests a combination of liver-directed therapy (D-TACE-HAIC), an immunotherapy drug (Envafolimab), and a targeted therapy pill (Lenvatinib) for people with a type of liver cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. The goal is to see if this combination can shrink or control the cancer.
This trial tests a combination of chemotherapy directly into the liver artery, an immunotherapy drug, and a targeted therapy pill before surgery for a type of bile duct cancer that has a high chance of coming back. The goal is to see if this approach can improve outcomes for patients whose cancer is still removable but has certain high-risk features.
This trial tests a combination of three treatments for a rare form of liver cancer that is both hepatocellular and cholangiocarcinoma: HAIC (chemotherapy given directly into the liver artery), Camrelizumab (an immunotherapy that helps your immune system attack cancer cells), and Rivoceranib (a targeted therapy that blocks blood vessel growth to tumors). It may be an option if you haven't had prior systemic therapy for this cancer and your liver function is stable.
Hear when a new Intrahepatic Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.